The detection panels between assays are very distinct, since the OncoBEAM-TM-RAS-CRC includes 34 frequent RAS (KRAS and NRAS) DNA alterations, Biorad's assay is restricted to alterations of KRAS on exon 2, and the 56G oncology panel provides the overall molecular profile of the patient in one assay [28, 29]. Here, KRAS is linked to colorectal carcinoma.